Beating Rebound Headaches: What the Network Meta-Analysis Says Actually Works

Medication-overuse headache (MOH) is, by the researchers' own description, the most common secondary headache disorder — meaning a headache caused by something else, in this case the very drugs people take to stop headaches. It is also, awkwardly, one of the conditions where the standard advice ("just stop taking them") collides with the lived reality of people who are taking them because their heads hurt. The new analysis didn't invent a cure. What it did was pool sixteen randomized controlled trials covering roughly 3,000 participants and rank the strategies by how many monthly headache days they actually subtract.

That last detail matters. Monthly headache days is the outcome migraine and headache researchers care about because it tracks the thing patients care about: how many days this month did your head hurt enough to wreck the day. Lowering that number is the whole game.

Single interventions — abrupt withdrawal alone, a preventive pill alone, education alone — were not the winners. The combinations were. According to the network meta-analysis, the top-ranked strategy paired abrupt withdrawal of the overused medication with an oral preventive drug and a greater occipital nerve block, a brief injection at the base of the skull. That bundle was associated with a reduction of about 10.6 monthly headache days versus control.

Close behind: restricting the overused acute medication while starting an oral preventive and a CGRP-targeted therapy — the newer class of migraine drugs that block calcitonin gene-related peptide, a signaling molecule implicated in migraine attacks. That combination came in at roughly 8.47 fewer monthly headache days versus control, per the same analysis.

Two patterns jump out. First, the strongest results come from stacking a withdrawal approach with a prevention approach — not picking one. Second, even the headline numbers are confidence intervals, not promises: the top bundle's interval ran roughly from a 6-day to a 15-day reduction. Real, but variable.

The logic is mechanistic, and the review authors are reasonably direct about it. Withdrawal addresses the driver — the daily or near-daily exposure to acute medications that appears to sensitize the pain system. Prevention addresses the underlying headache disorder that sent people reaching for those medications in the first place. Doing only one leaves the other half of the problem intact.

The greater occipital nerve block in the top-ranked bundle is best understood as a bridge: a short-term intervention to blunt the rebound period when people first cut back. CGRP therapies, in the second-ranked bundle, are doing something different — providing an ongoing preventive effect that reduces the temptation to reach for acute drugs at all. Different tools, similar strategic shape: take pressure off the acute-medication loop while you exit it.

This is where the editorial calibration matters. A network meta-analysis is a powerful design — it can compare treatments that were never tested head-to-head by chaining them through shared comparators — but it inherits the limits of its inputs. Sixteen trials and roughly 3,000 patients is a serviceable evidence base, not a definitive one. The authors assessed risk of bias using Cochrane's tool and ranked treatments by p-scores, which order strategies probabilistically rather than declaring a single winner.

Translation: the rankings are a best current read, not a final verdict. Expect them to shift as more head-to-head trials of CGRP-based regimens in MOH specifically report out. What is unlikely to flip is the broader signal — that combination strategies outperform solo ones — because that pattern is consistent across the network rather than resting on a single trial.

The defining feature of MOH is not a particular drug. It's the frequency. Headache specialists generally flag patterns like regular use of OTC analgesics on most days of the month, or triptans more than a couple of days per week, sustained over months. The reason it goes unrecognized is that the medication is doing its short-term job — each individual dose helps — while the cumulative pattern entrenches the headache disorder.

None of this is a do-it-yourself project, and the analysis is explicitly about clinician-managed strategies: which medication to withdraw, how abruptly, which preventive to start, whether to bridge with a nerve block or layer in a CGRP therapy. Those are decisions for a primary care doctor or headache specialist, not a supplement aisle. The useful thing a reader can do with this paper is walk into that appointment knowing the question to ask: what's our combination plan, not just our stop-the-pills plan.